Psychosomatic Department, Shanghai Changning Mental Health Center.
Psychiatry Department.
Clin Neuropharmacol. 2023;46(5):192-197. doi: 10.1097/WNF.0000000000000568. Epub 2023 Sep 12.
Depressive disorders constitute a series of debilitating diseases. This study investigated the therapeutic effect of agomelatine (AG) combined with aerobic exercise (AE) on patients with moderate-severe depression (MSD) and the changes of the serum C-reactive protein (CRP) level in patients after treatment as well as its significance.
A total of 178 MSD patients were randomly assigned to the AG group (N = 90) and AG + AE group (N = 88). The severity of depressive disorders and anhedonia was assessed using the Hamilton Rating Scale for Depression (HAM-D), Beck Depression Inventory, and Snaith-Hamilton Pleasure Scale scores. The serum CRP level in MSD patients was detected by turbidity assay. Patients were defined as remitters, responders, and nonresponders according to the HAM-D 17 score, and the treatment efficacy was analyzed, followed by evaluation of the serum CRP level in patients with different treatment responses. Finally, the adverse reactions of patients during treatment were statistically analyzed.
After treatment, the HAM-D, Beck Depression Inventory, and Snaith-Hamilton Pleasure Scale scores and the serum CRP level of the 2 groups were reduced, and changes in the AG + AE group was more significant than that in the AG group. The clinical efficacy of the AG + AE group was better than that of the AG group. After treatment, the serum levels of CRP in remitters and responders were reduced, but not significantly in nonresponders. The incidence of adverse events in the AG + AE group was lower than that in the AG group.
AG + AE reduced the serum level of CRP in MSD patients and had good therapeutic effects on MSD patients.
抑郁障碍是一系列使人虚弱的疾病。本研究探讨了阿莫拉汀(AG)联合有氧运动(AE)对中重度抑郁(MSD)患者的治疗效果以及治疗后患者血清 C 反应蛋白(CRP)水平的变化及其意义。
将 178 例 MSD 患者随机分为 AG 组(N=90)和 AG+AE 组(N=88)。采用汉密尔顿抑郁量表(HAM-D)、贝克抑郁量表和斯奈思-汉密尔顿快感量表评分评估抑郁障碍和快感缺失的严重程度。采用比浊法检测 MSD 患者血清 CRP 水平。根据 HAM-D17 评分将患者定义为缓解者、应答者和无应答者,分析治疗效果,然后评估不同治疗反应患者的血清 CRP 水平。最后,统计分析患者治疗期间的不良反应。
治疗后,两组 HAM-D、贝克抑郁量表和斯奈思-汉密尔顿快感量表评分及血清 CRP 水平均降低,AG+AE 组变化更为明显。AG+AE 组的临床疗效优于 AG 组。治疗后,缓解者和应答者的血清 CRP 水平降低,但无应答者无明显变化。AG+AE 组的不良反应发生率低于 AG 组。
AG+AE 降低了 MSD 患者的血清 CRP 水平,对 MSD 患者有良好的治疗效果。